PharmaLectures.com

Courses › Pharma training by role › Owner, CEO and board: everything Europe expects of you, in one course

Owner, CEO and board: everything Europe expects of you, in one course

Your board answers the inspector on the spot and hands over the minutes that prove it.

  • 10 audio modulesthree lengths each
  • 1 h 40 min to 8 h 20 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Owner, CEO and boardwho it is written for

Why this training matters

An inspector asks your directors how they oversee EudraLex Volume 4 Annex 1 sterile manufacturing. Nobody answers, and the silence goes into the report as a governance finding. The launch waits while you rebuild the quality system and the board's records.

What changes after this course

Your directors answer in the inspector's own terms and point to minutes showing what they reviewed and challenged. You hold a certificate for each learner and a training record for every person, ready for your compliance file. The board shows its oversight instead of describing it.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your directors read a quality report and spot the gap in EudraLex Volume 4 compliance before the inspector does. When the question turns to Annex 1 and sterile manufacturing, they point to minutes showing what the board reviewed and what it challenged. Your Qualified Person gets a board that asks sharper questions instead of nodding along.

The chief executive approves a research budget after checking it against Regulation (EU) No 536/2014, and stops the one that cannot pass. Market access plans start from the national health technology assessment, so a pricing error shows up at the table, not after launch. Directive 2001/83/EC duties get a named owner instead of drifting between departments.

When a patient data breach lands, the board already knows the General Data Protection Regulation steps and who takes them. Before a deal closes, your team asks for the inspection reports and the good manufacturing practice certificate, and reads them for what the seller left out. A recall under Chapter 8 starts with a team that knows its roles.

Investor questions on environmental and social governance get answers with figures behind them. And when the European Commission changes its digital rules for the supply chain, the board sees the decision early and budgets for it, rather than hearing about it first from a competitor.

Who needs this training

  • Chief Executive Officer

    An inspector asks how you personally oversee good manufacturing practice. You hand over the board minutes that show what you reviewed, what you questioned and what you decided.

  • Pharmaceutical Company Owner

    A merger target looks clean on paper. You ask for its inspection reports, spot the open EudraLex Volume 4 findings, and renegotiate or walk away before the liability becomes yours.

  • Board Director

    A shareholder asks how the new product meets national pricing and reimbursement rules. You explain the health technology assessment route yourself instead of passing the question to market access.

  • Chairperson of the Board

    A breach exposes patient trial records late on a Friday. You start the General Data Protection Regulation response at once, and the notification to the authority is not missed.

Roles: Owner, CEO and board

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Answer an inspector's governance questions in the terms of Directive 2001/83/EC and EudraLex Volume 4.
  2. Record board review and challenge of quality reports so oversight of Annex 1 sterile manufacturing is documented in the minutes.
  3. Reject a research budget that does not meet Regulation (EU) No 536/2014 on clinical trials.
  4. Test a clinical data system against the General Data Protection Regulation and Regulation (EU) No 536/2014.
  5. Name the inspection and licence documents to request before signing a European pharmaceutical acquisition.
  6. Assign the first-hour roles in a recall under EudraLex Volume 4 Chapter 8 and inform the national competent authority.

What the company gets

  • Your quality unit stops arguing for compliance budgets, because the board has already seen the reports and asked its own questions.
  • Inspectors receive documented proof of board oversight during the audit, not a promise to look for it afterwards.
  • Your deal team stops short of buying a site with open EudraLex Volume 4 findings, because it asked for the inspection history first.
  • Every learner holds a certificate and a training record, so your compliance file shows who completed which module and passed which questionnaire.
  • Launch plans start from the national health technology assessment, so pricing problems surface before the board approves the launch.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 10 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 40 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard4 h 10 min25 min a module, for regulatory, quality and business-development staff
Expanded8 h 20 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing1 h 40 min

Course outline: 10 modules

10 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Turn Directive 2001/83/EC duties into standing items on your board agenda

    • How to read a directive and see which duty lands on your board before it reaches your pipeline.
    • The Directive 2001/83/EC duties that need a named owner on your board, not just in the quality unit.
    • Why national agency differences decide your launch date, and how to ask about them early.
  2. 2Prove board oversight of EudraLex Volume 4 Good Manufacturing Practice

    • What to say when an inspector asks how the board oversees Annex 1 sterile manufacturing.
    • The quality reports worth reading in a board meeting, and the ones that only fill the pack.
    • How to record a board challenge in the minutes so the proof exists when someone asks for it.
  3. 3Prevent personal liability under national corporate governance codes

    • Why delegating compliance to the quality unit still leaves questions for the chief executive.
    • The board papers that show directors asked, checked and decided, kept where you can find them.
    • What to do when national company law and the governance code seem to ask for different things.
  4. 4Approve research budgets only when they meet Regulation (EU) No 536/2014

    • How to read a trial budget against Regulation (EU) No 536/2014 before you sign it.
    • The trial oversight records inspectors ask a sponsor for, and who on your board should have seen them.
    • When to pause a clinical investment, and when a fixable gap should not stop it.
  5. 5Build market access plans around national health technology assessments

    • How a national health technology assessment shapes the price you can defend in each country.
    • The market access evidence to demand from your team before the board approves a launch.
    • What to have in hand before reimbursement talks with a national health authority begin.
  6. 6Direct your crisis team through a recall under EudraLex Volume 4 Chapter 8

    • How to set up a crisis team that already knows who speaks, who decides and who calls the regulator.
    • What to do in the first hours after a national competent authority demands a recall.
    • Why a late public statement turns a quality issue into a story you no longer control.
  7. 7Enforce General Data Protection Regulation compliance across clinical data

    • How to test your clinical trial systems against the General Data Protection Regulation.
    • The Annex 11 data integrity checks that show your computerised systems can be trusted.
    • What to do the hour your information technology team reports a breach of patient records.
  8. 8Spot regulatory red flags before you sign a European acquisition

    • How to find the hidden compliance failure in a target company's inspection history before you sign.
    • The documents to ask for first, such as the manufacturing authorisation and the latest inspection reports.
    • Why buying a site with open inspection findings can stop your own supply, and what to put in the deal terms.
  9. 9Answer investor questions on environmental and social governance

    • How to report environmental impact so a European institutional investor finds the answer in one place.
    • What to say when shareholders press you on your manufacturing footprint and waste.
    • The social and environmental figures your annual report must back up when a shareholder asks.
  10. 10Adapt your supply chain to new European Commission digitalization rules

    • How to read a new European Commission digitalization rule and see the board decision hiding in it.
    • The digital supply chain changes worth budgeting for now, and the ones that can safely wait.
    • Why an old compliance model leaves you slower than competitors who already changed theirs.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

10 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 40 min in the briefing length and 8 h 20 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Owner, CEO and board. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 90 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team